ScholarLens Back to search
2023•Gynecologic OncologyOpen access

Leave it in the past: Primary treatment modality for high-grade epithelial ovarian cancer does not affect secondary cytoreduction outcomes (173)

Beryl Manning‐Geist, Tiffany Sia, Sarah Ehmann, Carrie Luardo, Aaron Praiss, Jessica A. Lavery, Alexia Iasonos, Yukio Sonoda, Rachel N. Grisham, Oliver Zivanovic, Kara Long Roche, Ginger J. Gardner, Dennis Chi

Open full text 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

Open-access reader

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Medicine, Debulking, Epithelial ovarian cancer, Ovarian cancer, Primary treatment, Surgery, Cytoreductive surgery, Oncology

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Leave it in the past: Primary treatment modality for high-grade epithelial ovarian cancer does not affect secondary cytoreduction outcomes (173) — Research Paper | ScholarLens